Christopher Mohr
Christopher Mohr
Verified email at uni-tuebingen.de
Title
Cited by
Cited by
Year
OptiType: precision HLA typing from next-generation sequencing data
A Szolek, B Schubert, C Mohr, M Sturm, M Feldhahn, O Kohlbacher
Bioinformatics 30 (23), 3310-3316, 2014
2762014
Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient
MW Löffler, PA Chandran, K Laske, C Schroeder, I Bonzheim, M Walzer, ...
Journal of hepatology 65 (4), 849-855, 2016
452016
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
MW Löffler, C Mohr, L Bichmann, LK Freudenmann, M Walzer, ...
Genome Medicine 11 (1), 28, 2019
262019
FRED 2: an immunoinformatics framework for Python
B Schubert, M Walzer, HP Brachvogel, A Szolek, C Mohr, O Kohlbacher
Bioinformatics 32 (13), 2044-2046, 2016
212016
qPortal: A platform for data-driven biomedical research
C Mohr, A Friedrich, D Wojnar, E Kenar, AC Polatkan, MC Codrea, ...
PloS one 13 (1), e0191603, 2018
112018
ImmunoNodes–graphical development of complex immunoinformatics workflows
B Schubert, L de la Garza, C Mohr, M Walzer, O Kohlbacher
BMC bioinformatics 18 (1), 1-7, 2017
72017
MHCquant: Automated and reproducible data analysis for immunopeptidomics
L Bichmann, A Nelde, M Ghosh, L Heumos, C Mohr, A Peltzer, ...
Journal of proteome research 18 (11), 3876-3884, 2019
62019
ClinOmicsTrailbc: a visual analytics tool for breast cancer treatment stratification
L Schneider, T Kehl, K Thedinga, NL Grammes, C Backes, C Mohr, ...
Bioinformatics 35 (24), 5171-5181, 2019
32019
Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy
F Blaeschke, MC Paul, MU Schuhmann, A Rabsteyn, C Schroeder, ...
Cytotherapy 21 (9), 973-986, 2019
32019
Ws-pgrade/guse-based science gateways in teaching
SD Olabarriaga, A Benabdelkader, MWA Caan, MM Jaghoori, J Krüger, ...
Science Gateways for Distributed Computing Infrastructures, 223-234, 2014
32014
iVacALL: utilizing next-generation sequencing for the establishment of an individual peptide vaccination approach for paediatric acute lymphoblastic leukaemia
C Kyzirakos, U Pflückhahn, M Sturm, C Schroeder, P Bauer, M Walter, ...
Bone Marrow Transplantation 48, S401, 2013
22013
qPortal–A science gateway for biomedical applications
C Mohr, A Friedrich, D Wojnar, E Kenar, AC Polatkan, MC Codrea, ...
PeerJ PrePrints, 2017
12017
Optimized neoantigen selection based on tumor exome data
C Kyzirakos, C Mohr, S Armeanu-Ebinger, M Feldhahn, D Hadaschik, ...
Annals of Oncology 27 (suppl_6), 1097P, 2016
12016
Abstract B124: Personalized peptide vaccination based on patient-individual tumor-specific variants induces T-cell responses in pediatric patients
A Rabsteyn, C Kyzirakos, C Schroeder, M Sturm, C Mohr, J Matthes, ...
Cancer Immunology Research 7 (2 Supplement), B124-B124, 2019
2019
Abstract CT057: Phase I trial to evaluate the feasibility and safety of an individualized peptide vaccine of unmodified cancer antigens: PepIVAC-01
S Haen, MW Löffler, O Kohlbacher, S Nahnsen, C Mohr, M Stieglbaueren, ...
Cancer Research 78 (13 Supplement), CT057-CT057, 2018
2018
Number of predicted tumour-neoantigens as biomarker for cancer immunotherapies
S Armeanu-Ebinger, D Hadaschik, C Kyzirakos, C Mohr, F Battke, ...
Annals of Oncology 28, vii12, 2017
2017
Erratum to “Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient”
MW Löffler, PA Chandran, K Laske, C Schroeder, I Bonzheim, M Walzer, ...
Journal of hepatology 66 (1), 252-253, 2017
2017
Personalized peptide-vaccination for pediatric acute lymphoblastic leukemia patients based on patient-individual tumor-specific variants (iVacALL)
P Lang, A Rabsteyn, C Kyzirakos, C Schroeder, M Sturm, C Mohr, ...
ONCOLOGY RESEARCH AND TREATMENT 39, 125-125, 2016
2016
iVacALL: A personalized peptide-vaccination design platform for pediatric acute lymphoblastic leukemia patients based on patient-individual tumor specific variants
A Rabsteyn, C Kyzirakos, C Schroeder, M Sturm, C Mohr, M Walzer, ...
CANCER IMMUNOLOGY RESEARCH 4 (1), 2016
2016
Abstract A113: iVacALL: A personalized peptide-vaccination design platform for pediatric acute lymphoblastic leukemia patients based on patient-individual tumor-specific variants
A Rabsteyn, C Kyzirakos, C Schröder, M Sturm, C Mohr, M Walzer, ...
Cancer Immunology Research 4 (1 Supplement), A113-A113, 2016
2016
The system can't perform the operation now. Try again later.
Articles 1–20